BioPharmSignal logoBioPharmSignal

Biotech News

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Company update

– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV

Related news

PTCTPTC Therapeutics, Inc.2026-08-12 20:01 EST

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

RAREUltragenyx Pharmaceutical2026-09-01 20:05 EST

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

BIIBBiogen2026-05-14 12:35 EST

Biogen Completes Acquisition of Apellis Pharmaceuticals

RAREUltragenyx Pharmaceutical2026-08-19 21:21 EST

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

BIIBBiogen2026-08-06 22:15 EST

Biogen Completes Acquisition of RayThera Inc.

ABEOAbeona Therapeutics2026-09-18 11:30 EST

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

ARWRArrowhead Pharmaceuticals2026-07-27 11:30 EST

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

MNPRMonopar2026-07-22 12:00 EST

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-09-21 20:30 EST

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-08-24 12:00 EST

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTCTPTC Therapeutics, Inc.2026-08-12 20:01 EST

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Stock data

Close
65.37 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States